# Wuhan Togo Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuhan-togo-biotechnology-co

- Industry: Medical Devices & Equipment
- Headquarters: Wuhan, China
- Website: www.whtogo.com
- Total disclosed funding: $9.4M
- Latest round: Series B (Jul 29, 2022)
- Investors on record: 3

## About

Founded in 2013 and based in Wuhan, China, Wuhan Togo Biotechnology Co., Ltd is a medical equipment company that focuses on R&D of the artificial livers. The company was established by professor Ping Zhou who is a deputy director at the Institute of Organ Transplantation, Tongji Hospital. The company has 300 square meters production workshop with GMP level, for manufacturing human-derived hepatoblast cells. As of July 2022, the company has raised three rounds of funding.

The company provides artificial livers for chronic or acute liver failure. The company developed artificial livers, HepAssis2, and mass production of human-derived hepatoblast cells.  

The company plans to build an artificial hepatocyte production factory in Chongqing, set up additional offices in Chongqing, raise CNY 200 million in series B1 funding by the end of 2022, and prepare to list on the Hong Kong Stock Exchange in 2023.

## Funding rounds

- Series B, Jul 29, 2022, $8.9M — Toposcend Capital, Pixiu Group
- Angel, Jul 3, 2015, $0.5M — Xinshengda Capital

## Investors

- Xinshengda Capital (https://capitalatlas.ai/funds/xinshengda-capital) — Angel
- Toposcend Capital (https://capitalatlas.ai/funds/toposcend-capital) — Series B
- Pixiu Group — Series B